Literature DB >> 20039183

Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Anthony S Russell1, Wojtek P Olszynski, K S Davison, Cheryl Koehn, Boulos Haraoui.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20039183     DOI： 10.1007/s10067-009-1338-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  67 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 2.  The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

Authors:  Gerald Gartlehner; Richard A Hansen; Beth L Jonas; Patricia Thieda; Kathleen N Lohr
Journal:  J Rheumatol       Date:  2006-12       Impact factor: 4.666

3.  Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population.

Authors:  Till Uhlig; Jon H Loge; Ivar S Kristiansen; Tore K Kvien
Journal:  J Rheumatol       Date:  2007-05-15       Impact factor: 4.666

4.  Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.

Authors:  Daniel E Furst; Norman Gaylis; Vance Bray; Ewa Olech; David Yocum; Jeffrey Ritter; Michael Weisman; Daniel J Wallace; John Crues; Dinesh Khanna; Gregory Eckel; Newman Yeilding; Peter Callegari; Sudha Visvanathan; Jeannie Rojas; Ronald Hegedus; Laura George; Khalid Mamun; Keith Gilmer; Orrin Troum
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

Review 5.  What have we learnt about the development and progression of early RA from RCTs?

Authors:  David L Scott
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-02       Impact factor: 4.098

6.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

7.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

8.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.

Authors:  Mark A Quinn; Philip G Conaghan; Philip J O'Connor; Zunaid Karim; Adam Greenstein; Andrew Brown; Clare Brown; Alexander Fraser; Stephen Jarret; Paul Emery
Journal:  Arthritis Rheum       Date:  2005-01

9.  Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Authors:  E Keystone; P Emery; C G Peterfy; P P Tak; S Cohen; M C Genovese; M Dougados; G R Burmester; M Greenwald; T K Kvien; S Williams; D Hagerty; M W Cravets; T Shaw
Journal:  Ann Rheum Dis       Date:  2008-04-03       Impact factor: 19.103

10.  Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.

Authors:  Maria Pilar Lisbona; Joan Maymo; Javier Perich; Miriam Almirall; Carolina Pérez-García; Jordi Carbonell
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666
View more
  2 in total

1.  High disease activity may not be sufficient to escalate care.

Authors:  Liana Fraenkel; Meaghan Cunningham
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

2.  Networks of Care: A Social Network Perspective of Distributed Multidisciplinary Care for People With Inflammatory Arthritis.

Authors:  Wendy Hartford; Catherine L Backman; Linda C Li; Shanon McQuitty; Annette McKinnon; Raheem Kherani; Laura Nimmon
Journal:  ACR Open Rheumatol       Date:  2021-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.